TY - JOUR
T1 - New Quinone antibiotics against methicillin-resistant s. Aureus
AU - Campanini-Salinas, Javier
AU - Andrades-Lagos, Juan
AU - Hinojosa, Nicolás
AU - Moreno, Fabián
AU - Alarcón, Pedro
AU - González-Rocha, Gerardo
AU - Burbulis, Ian E.
AU - Vásquez-Velásquez, David
N1 - Funding Information:
Funding: This research was funded by FONDECYT grant numbers 11110516 (D.V.-V.) and 79100006 (D.V.-V.).
Funding Information:
Acknowledgments: The authors gratefully acknowledge support by the Agencia Nacional de In-vestigación y Desarrollo (ANID) de Chile through a FONDECYT Iniciación en Investigación Grant No. 11110516 (D.V.-V.), Chile; FONDECYT Proyecto de Inserción Grant No. 79100006 (D.V.-V.), Chile; Programa de Estímulo a la Excelencia Institucional PEEI 2017, Universidad de Chile (D.V.-V.); and FONDECYT Regular Grant No. 1191737 (I.E.B.). The authors also gratefully acknowledge support from CONICYT de Chile in the form of a Beca Doctorados Nacional No. 21130643 (J.C.-S.) and 21130628 (J.A.-L.). The authors lastly acknowledge contributing support from the McDonnell foundation though a Fellowship from the Salk Institute (I.E.B.) and the National Institute of Allergy and Infectious Disease of the United States of America National Institutes of Health under award number NIH 7R21AI111072 (I.E.B.).
Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
PY - 2021/6
Y1 - 2021/6
N2 - There is an urgent need for the development of new antibiotics. Here, we describe the inhibitory activity of new quinone compounds against methicillin-resistant Staphylococcus aureus (ATCC® 43300), methicillin-sensitive S. aureus (ATCC® 29213), and two clinical isolates from Chile (ISP-213 and ISP-214). We observed 99.9% reduction in viability within 2 h of exposure without the cultures exhibiting any post-antibiotic effect, which was twice the kinetics to that observed with vancomycin. These clinical isolates did not acquire resistance to these quinone derivatives during the course of our study. We found that these compounds protected larvae of the greater wax moth, sp. Galleria mellonella, from infection by these MRSA clinical strains as effectively as vancomycin. These quinone derivatives are potential drug candidates worth further development.
AB - There is an urgent need for the development of new antibiotics. Here, we describe the inhibitory activity of new quinone compounds against methicillin-resistant Staphylococcus aureus (ATCC® 43300), methicillin-sensitive S. aureus (ATCC® 29213), and two clinical isolates from Chile (ISP-213 and ISP-214). We observed 99.9% reduction in viability within 2 h of exposure without the cultures exhibiting any post-antibiotic effect, which was twice the kinetics to that observed with vancomycin. These clinical isolates did not acquire resistance to these quinone derivatives during the course of our study. We found that these compounds protected larvae of the greater wax moth, sp. Galleria mellonella, from infection by these MRSA clinical strains as effectively as vancomycin. These quinone derivatives are potential drug candidates worth further development.
KW - Drug discovery
KW - Methicillin-resistant S. aureus (MRSA)
KW - Quinone-antibiotics
UR - http://www.scopus.com/inward/record.url?scp=85107207325&partnerID=8YFLogxK
U2 - 10.3390/antibiotics10060614
DO - 10.3390/antibiotics10060614
M3 - Article
AN - SCOPUS:85107207325
SN - 2079-6382
VL - 10
JO - Antibiotics
JF - Antibiotics
IS - 6
M1 - 614
ER -
